ezetimibe 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antihyperlipidaemics, acyl CoA: cholesterol acyltransferase (ACAT) inhibitors	1125	163222-33-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: SCH58235 SCH-58235 ezetimib ezetimibe ezedoc ezentia ezetrol zetia	An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS. Molecular weight: 409.43 Formula: C24H21F2NO3 CLOGP: 3.96 LIPINSKI: 0 HAC: 4 HDO: 2 TPSA: 60.77 ALOGS: -4.68 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

SCH58235
SCH-58235
ezetimib
ezetimibe
ezedoc
ezentia
ezetrol
zetia

An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.

Molecular weight: 409.43
Formula: C24H21F2NO3
CLOGP: 3.96
LIPINSKI: 0
HAC: 4
HDO: 2
TPSA: 60.77
ALOGS: -4.68
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
EoM (Fraction excreted unchanged in urine)	2 %	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.35 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
S (Water solubility)	0.01 mg/mL	Bocci G, Oprea TI, Benet LZ

Showing 1 to 5 of 5 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
April 18, 2007	PMDA	Schering-Plough K.K
Oct. 25, 2002	FDA	MSD INTL GMBH

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myalgia	1057.60	10.64	1020	66512	145509	63275981
Rhabdomyolysis	679.06	10.64	477	67055	43474	63378016
Blood creatine phosphokinase increased	396.43	10.64	298	67234	30132	63391358
Low density lipoprotein increased	232.00	10.64	120	67412	6237	63415253
Contraindicated product administered	175.81	10.64	15	67517	217633	63203857
Muscle spasms	173.28	10.64	458	67074	155692	63265798
Pemphigus	168.79	10.64	6	67526	183720	63237770
Maternal exposure during pregnancy	160.39	10.64	22	67510	220040	63201450
Coronary artery disease	148.97	10.64	178	67354	32199	63389291
Angina pectoris	132.89	10.64	162	67370	29916	63391574

Showing 1 to 10 of 284 entries

Previous1 2 3 4 5…29Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myalgia	1111.98	11.13	1013	58944	83097	34813877
Rhabdomyolysis	543.47	11.13	626	59331	67537	34829437
Blood creatine phosphokinase increased	540.74	11.13	514	59443	44343	34852631
Myopathy	310.58	11.13	212	59745	11342	34885632
Low density lipoprotein increased	224.24	11.13	122	59835	4314	34892660
Myocardial infarction	156.64	11.13	510	59447	120575	34776399
Angina pectoris	146.72	11.13	222	59735	31141	34865833
Coronary artery disease	139.29	11.13	276	59681	48029	34848945
Off label use	125.12	11.13	341	59616	419183	34477791
Muscular weakness	117.61	11.13	332	59625	72565	34824409

Showing 1 to 10 of 213 entries

Previous1 2 3 4 5…22Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myalgia	1695.41	10.52	1608	101810	184033	79456937
Rhabdomyolysis	1047.50	10.52	949	102469	102182	79538788
Blood creatine phosphokinase increased	725.87	10.52	636	102782	65454	79575516
Myopathy	388.97	10.52	273	103145	20290	79620680
Low density lipoprotein increased	353.90	10.52	188	103230	8434	79632536
Coronary artery disease	255.50	10.52	367	103051	65107	79575863
Myocardial infarction	253.71	10.52	663	102755	183466	79457504
Angina pectoris	238.00	10.52	314	103104	51418	79589552
Muscular weakness	200.49	10.52	558	102860	160171	79480799
Off label use	198.19	10.52	566	102852	906649	78734321

Showing 1 to 10 of 371 entries

Previous1 2 3 4 5…38Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	C10AX09	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Other lipid modifying agents
ATC	C10BA02	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Combinations of various lipid modifying agents
ATC	C10BA05	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Combinations of various lipid modifying agents
ATC	C10BA06	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Combinations of various lipid modifying agents
ATC	C10BA10	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Combinations of various lipid modifying agents
ATC	C10BA11	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Combinations of various lipid modifying agents
ATC	C10BA12	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Combinations of various lipid modifying agents
CHEBI has role	CHEBI:35221	antimetabolite
CHEBI has role	CHEBI:35679	antilipemic drugs
CHEBI has role	CHEBI:35821	anticholesteremic drugs

Showing 1 to 10 of 16 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Hypercholesterolemia	indication	13644009
Hyperlipidemia	indication	55822004	DOID:1168
Familial hypercholesterolemia - homozygous	indication	238078005
Familial hypercholesterolemia - heterozygous	indication	238079002
Sitosterolemia	indication	238104009	DOID:0090019
Mixed hyperlipidemia	indication	267434003
Alopecia areata	off-label use	68225006	DOID:986
Alcoholism	contraindication	7200002
Acute nephropathy	contraindication	58574008
Disorder of muscle	contraindication	129565002	DOID:423

Showing 1 to 10 of 20 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.48	acidic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
10MG	ZETIA	ORGANON	N021445	Oct. 25, 2002	RX	TABLET	ORAL	7612058	Oct. 30, 2025	REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL
10MG	ZETIA	ORGANON	N021445	Oct. 25, 2002	RX	TABLET	ORAL	7612058	Oct. 30, 2025	TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
10MG;EQ 10MG BASE	ROSZET	ALTHERA PHARMS	N213072	March 23, 2021	DISCN	TABLET	ORAL	10376470	May 1, 2033	TREATMENT OF HYPERLIPIDEMIA
10MG;EQ 10MG BASE	ROSZET	ALTHERA PHARMS	N213072	March 23, 2021	DISCN	TABLET	ORAL	9763885	May 1, 2033	TREATMENT OF HYPERLIPIDEMIA
10MG;EQ 20MG BASE	ROSZET	ALTHERA PHARMS	N213072	March 23, 2021	DISCN	TABLET	ORAL	10376470	May 1, 2033	TREATMENT OF HYPERLIPIDEMIA
10MG;EQ 20MG BASE	ROSZET	ALTHERA PHARMS	N213072	March 23, 2021	DISCN	TABLET	ORAL	9763885	May 1, 2033	TREATMENT OF HYPERLIPIDEMIA
10MG;EQ 40MG BASE	ROSZET	ALTHERA PHARMS	N213072	March 23, 2021	DISCN	TABLET	ORAL	10376470	May 1, 2033	TREATMENT OF HYPERLIPIDEMIA
10MG;EQ 40MG BASE	ROSZET	ALTHERA PHARMS	N213072	March 23, 2021	DISCN	TABLET	ORAL	9763885	May 1, 2033	TREATMENT OF HYPERLIPIDEMIA
10MG;EQ 5MG BASE	ROSZET	ALTHERA PHARMS	N213072	March 23, 2021	DISCN	TABLET	ORAL	10376470	May 1, 2033	TREATMENT OF HYPERLIPIDEMIA
10MG;EQ 5MG BASE	ROSZET	ALTHERA PHARMS	N213072	March 23, 2021	DISCN	TABLET	ORAL	9763885	May 1, 2033	TREATMENT OF HYPERLIPIDEMIA

Showing 1 to 10 of 16 entries

Previous1 2Next

Orange Book exclusivity data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
180MG;10MG	NEXLIZET	ESPERION THERAPS INC	N211617	Feb. 26, 2020	RX	TABLET	ORAL	Feb. 26, 2023	NEW PRODUCT
180MG;10MG	NEXLIZET	ESPERION THERAPS INC	N211617	Feb. 26, 2020	RX	TABLET	ORAL	Feb. 21, 2025	NEW CHEMICAL ENTITY

Showing 1 to 2 of 2 entries

Previous1Next

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Niemann-Pick C1-like protein 1	Membrane other	Q9UHC9	NPCL1_HUMAN	ANTAGONIST	Kd	6.66	IUPHAR	CHEMBL
Sodium/bile acid cotransporter	Transporter	Q14973	NTCP_HUMAN		Ki	4.60	CHEMBL
Niemann-Pick C1-like protein 1	Unclassified		NPCL1_RAT		Ki	6.70	CHEMBL

Showing 1 to 3 of 3 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
009817	NDDF
150311	PUBCHEM_CID
17026	MMSL
229065	MMSL
341248	RXNORM
4021366	VUID
4021366	VANDF
408041006	SNOMEDCT_US
409149001	SNOMEDCT_US
45364	MMSL

Showing 1 to 10 of 22 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ezetimibe	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3713	TABLET	10 mg	ORAL	ANDA	26 sections
Ezetimibe	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8300	TABLET	10 mg	ORAL	ANDA	27 sections
Ezetimibe	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8300	TABLET	10 mg	ORAL	ANDA	27 sections
Ezetimibe	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5690	TABLET	10 mg	ORAL	ANDA	27 sections
Ezetimibe	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6664	TABLET	10 mg	ORAL	ANDA	28 sections
Ezetimibe	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7103	TABLET	10 mg	ORAL	ANDA	26 sections
Ezetimibe	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7103	TABLET	10 mg	ORAL	ANDA	26 sections
Ezetimibe	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7103	TABLET	10 mg	ORAL	ANDA	26 sections
Ezetimibe	Human Prescription Drug Label	1	16714-813	TABLET	10 mg	ORAL	ANDA	28 sections
Ezetimibe	Human Prescription Drug Label	1	16714-813	TABLET	10 mg	ORAL	ANDA	28 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next